Kevin Noonan, Jun 27, 2012
The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding generic drugs. This threat is posed by the practice of “reverse payments” in ANDA litigation. Typically, in these arrangements a branded drug manufacturer settles litigation with a generic challenger brought under the Hatch-Waxman Act and such settlements often involve a payment from the branded to the generic drug maker.
In the FTCR
...THIS ARTICLE IS AVAILABLE TO CPI SUBSCRIBERS
Please verify email or join us to access premium content!